CMS Chemical Aversion Therapy Coverage Policy for Alcoholism Treatment (NCD 30) — What Changed in 2026

CMS has issued a modification to National Coverage Determination (NCD) 30, which governs Medicare coverage of chemical aversion therapy for the treatment of alcoholism. This update affects how A/MACs adjudicate claims for inpatient and outpatient chemical aversion therapy services billed under the Outpatient Hospital Services benefit category. If your facility offers multi-modality addiction treatment programs that include chemical aversion therapy, this policy belongs on your compliance radar now.

What Is Chemical Aversion Therapy Under CMS NCD 30?

Chemical aversion therapy is a behavior modification technique that facilitates alcohol abstinence by conditioning patients to develop aversions to the taste, smell, and sight of alcoholic beverages. Clinically, this is achieved by repeatedly pairing alcohol exposure with unpleasant physiological symptoms—most commonly nausea—induced by chemical agents.

The three drugs most frequently used in this therapy are emetine, apomorphine, and lithium. It's worth noting a critical compliance detail: none of these drugs have received FDA approval specifically for use in chemical aversion therapy for alcoholism. That regulatory gap has direct implications for documentation and medical observation requirements, which we'll cover below.

Because of the demands this therapy places on patients and the unapproved-use status of the drugs involved, CMS requires that patients undergoing treatment be kept under medical observation throughout the process.

Medicare Coverage Criteria for Chemical Aversion Therapy

The Centers for Medicare & Medicaid Services covers chemical aversion therapy when it is determined to be reasonable and necessary for an individual patient. That language is doing a lot of work here—coverage is not automatic, and there are specific conditions your team must meet.

Physician certification is required. Because chemical aversion therapy is demanding and may not be appropriate for all Medicare beneficiaries seeking alcoholism treatment, a physician must certify that the therapy is appropriate for the specific patient. This certification isn't optional documentation to gather after the fact—it must be established before treatment and maintained in the medical record.

Context matters: multi-modality programs get the strongest coverage support. CMS's medical consultants specifically noted that chemical aversion therapy is most effective as part of multi-modality treatment programs that also include psychotherapy and other behavioral techniques. Facilities billing for this service as part of a comprehensive alcoholism treatment program are on the strongest coverage footing. For additional context on multi-modality program coverage, CMS cross-references §130.1 of its claims processing guidance.

Outpatient is the expected default for follow-up. The policy is explicit that follow-up chemical aversion therapy treatments can generally be provided on an outpatient basis. This means outpatient billing is the expected norm for ongoing treatment episodes, not inpatient.

Inpatient vs. Outpatient Billing: A Critical Distinction Under NCD 30

This is where revenue cycle teams can run into problems. CMS makes a clear level-of-care distinction that affects how you bill and what documentation you need.

Inpatient admission is covered—but requires individualized documentation. When it is medically necessary for a patient to receive chemical aversion therapy in a hospital inpatient setting, that level of care is available under Medicare. However, the physician must document the specific clinical reason the individual patient requires inpatient admission. A general preference for inpatient care won't satisfy this requirement.

A/MACs make necessity determinations—and QIOs can override them. Decisions about reasonableness, necessity, and appropriate level of care are made by Administrative/Medicare Administrative Contractors (A/MACs) based on accepted medical practice, with input from their medical consultants. In hospitals subject to Quality Improvement Organization (QIO) review, QIO determinations of medical necessity and level-of-care appropriateness are binding on A/MACs for claim adjudication. If your facility operates under QIO review, the QIO's decision controls—not the A/MAC's independent judgment.

This two-track adjudication process matters for your appeals strategy if a claim is denied.

Benefit Category: Outpatient Hospital Services Incident to a Physician's Service

Chemical aversion therapy falls under the Medicare benefit category of Outpatient Hospital Services Incident to a Physician's Service. This classification has billing implications for how services are reported and what supporting documentation ties the therapy to physician oversight. Because the drugs used are not FDA-approved for this specific indication, documentation of physician oversight and medical observation isn't just good practice—it's a coverage requirement baked into the policy itself.

Affected Codes

The policy does not list specific CPT or HCPCS codes, and no ICD-10-CM codes are enumerated in NCD 30. Billing teams should work with their coding resources and A/MAC guidance to identify the appropriate procedure codes for chemical aversion therapy services at their facility type.

When reporting these services, ensure all claims are supported by:

• Physician certification of medical necessity
• Documentation of the specific chemical agent used
• Evidence of medical observation during treatment
• Level-of-care justification if billing inpatient

What Your Billing Team Should Do